Condition

Stage IIIA Non-Small Cell Lung Cancer AJCC v7

ClinicalTrials.gov condition label

Clinical trials11

Recruiting0

Common interventions25

Lead sponsors shown9

Clinical trials

11 shown

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung CancerNCT03455556 · 2018-08-10

TERMINATED

Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung CancerNCT03348748 · 2017-12-18

TERMINATED

Collection of Blood Samples in Patients With Non-small Cell Lung CancerNCT03492801 · 2017-12-11

TERMINATED

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaNCT03229278 · 2017-10-03

COMPLETED

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or MesotheliomaNCT02408016 · 2015-05-22

TERMINATED

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerNCT02225405 · 2015-04-03

COMPLETED

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23

ACTIVE_NOT_RECRUITING

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung CancerNCT01993810 · 2014-01-03

ACTIVE_NOT_RECRUITING

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerNCT01822496 · 2013-11-04

TERMINATED

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerNCT01727076 · 2013-02-15

COMPLETED

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung CancerNCT01629498 · 2012-09-17

ACTIVE_NOT_RECRUITING

Common interventions

Laboratory Biomarker AnalysisOTHER9CisplatinDRUG3CarboplatinDRUG2CrizotinibDRUG2EtoposideDRUG2PaclitaxelDRUG2Photon Beam Radiation TherapyRADIATION2Proton Beam Radiation TherapyRADIATION2Quality-of-Life AssessmentOTHER2Questionnaire AdministrationOTHER2AldesleukinBIOLOGICAL1Anetumab RavtansineBIOLOGICAL1AtezolizumabBIOLOGICAL1Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn LymphocytesBIOLOGICAL1Biospecimen CollectionPROCEDURE1Clinical ObservationOTHER1CyclophosphamideDRUG1DocetaxelDRUG1DurvalumabBIOLOGICAL1Enzyme Inhibitor TherapyDRUG1ErlotinibDRUG1Image Guided Radiation TherapyRADIATION1Intensity-Modulated Radiation TherapyRADIATION1NintedanibDRUG1NivolumabBIOLOGICAL1

Leading sponsors

M.D. Anderson Cancer Center2National Cancer Institute (NCI)2ECOG-ACRIN Cancer Research Group1Fred Hutchinson Cancer Center1Mayo Clinic1Radiation Therapy Oncology Group1Roswell Park Cancer Institute1Rutgers, The State University of New Jersey1University of Southern California1

Trial status mix

TERMINATED5

ACTIVE_NOT_RECRUITING3

COMPLETED3

Phase mix

PHASE16

PHASE23

PHASE32

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.